
Seno Medical Instruments, Inc. is a San Antonio-based medical imaging company specializing in opto-acoustic imaging technology for cancer diagnosis, primarily breast cancer. Their flagship product, the FDA-approved Imagio® Breast Imaging System, fuses opto-acoustic imaging with ultrasound to provide earlier, more precise detection of malignant tissue, reducing negative biopsies and improving patient experience. The company holds core patents in opto-acoustic technology and aims to expand applications to other cancers. Their business model is focused on commercializing this innovative imaging modality through sales and training support. Seno's management team has extensive medical device commercialization experience, and the company has achieved regulatory approvals in the U.S. and Europe, positioning it as a leader in functional cancer imaging technology.

Seno Medical Instruments, Inc. is a San Antonio-based medical imaging company specializing in opto-acoustic imaging technology for cancer diagnosis, primarily breast cancer. Their flagship product, the FDA-approved Imagio® Breast Imaging System, fuses opto-acoustic imaging with ultrasound to provide earlier, more precise detection of malignant tissue, reducing negative biopsies and improving patient experience. The company holds core patents in opto-acoustic technology and aims to expand applications to other cancers. Their business model is focused on commercializing this innovative imaging modality through sales and training support. Seno's management team has extensive medical device commercialization experience, and the company has achieved regulatory approvals in the U.S. and Europe, positioning it as a leader in functional cancer imaging technology.
Headquarters: San Antonio, Texas
Flagship product: Imagio Breast Imaging System (opto-acoustic + ultrasound)
Regulatory status: FDA PMA cleared (January 2021) and CE Mark (April 2014)
Founded: September 2005
Total disclosed funding: USD 60,730,000 (last disclosed round Series C, Feb 2014)
Cancer imaging and diagnostics, with initial focus on breast cancer.
2005
Medical imaging / Medical devices
Series C announced Feb 2014; third-party reporting referenced ~ $34.6M of a $39M Series C in coverage.
2000000.00 USD
State award to further develop technology.
1000000.00 USD
Subsequent disbursement from TETF.
“Mix of state funding (Texas Emerging Technology Fund), angel/medical-community investors, and venture investors including MedCare Investment Funds”